ReviewGut microbes2025
Precision microbiota therapy for IBD: premise and promise.
Review in Gut microbes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Gut microbiota metabolites in the immunoregulation of enteritis: research progress.Frontiers in immunology · 2025Pooled it
- High-throughput analyses ofGut microbes · 2026Article
- ROS-responsive small-molecule self-assembled nanocarrier-integrated hydrogels for ulcerative colitis treatment.Materials today. Bio · 2026Article
- Development of Dithioacetal-Modified Dihydropyrimidone Derivatives with Potential Anti-Inflammatory Activity for Inflammatory Bowel Disease.Chemistry & biodiversity · 2026Article
- Review
- Erythritol Exacerbates DSS-Induced Colitis and Influences Behavioral Responses in Mice Through Gut Microbiota and Metabolic Alterations.Microorganisms · 2026Article
- Pro-Inflammatory Cytokines as Core Mediators of Colonic Epithelial Barrier Dysfunction: Roles of TNF-α, IFN-γ, IL-1β, and IL-6.International journal of molecular sciences · 2026Review
- The Gut-Liver Axis in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Mechanisms, Microbiome Interactions and Therapeutic Targets.Probiotics and antimicrobial proteins · 2026Review
- Gut Microbiota in Irritable Bowel Syndrome and Inflammatory Bowel Disease: Differences in Pathophysiology, Biomarkers, and Treatment Implications.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Crohn's Disease and Ulcerative Colitis: From Pathophysiology to Novel Therapeutic Approaches (3rd Edition).Biomedicines · 2026Article
- Article
- A web-based prediction model using routinely available clinical variables to estimate surgical risk in Crohn's disease during remission or mild activity.Scientific reports · 2026Article
- Human DNA levels in feces reflect gut inflammation and associate with presence of gut species in IBD patients across the age spectrum.Microbiome · 2026Article
- Flos sophorae immaturus exosome-like nanovesicles alleviate ulcerative colitis by attenuating intestinal oxidative stress and inflammation through activating Aryl hydrocarbon receptor via gut microbiota and tryptophan metabolism regulation.Journal of nanobiotechnology · 2026Article
- Mucosa-associated bacteria and metabolites in inflammatory bowel disease: from inside to insight.NPJ biofilms and microbiomes · 2026Review
- Inflammatory bowel diseases: pathological mechanisms and therapeutic perspectives.Molecular biomedicine · 2026Review
- Fecal microbiota transplantation: from empirical remedy to precision medicine.Frontiers in microbiomes · 2026Review
- Fecal microbiota transplantation in ulcerative colitis: mucosal immune mechanisms and precision microbiota therapy.Frontiers in immunology · 2026Review
- Fatty acid-binding protein 2 in inflammatory bowel disease: mechanistic insights and translational perspectives.Frontiers in medicine · 2026Review
- Research Progress of Transcutaneous Auricular Vagus Nerve Stimulation in Chronic Pain Management: A Narrative Review.Journal of pain research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Inflammatory Bowel Disease (IBD) is a spectrum of chronic inflammatory diseases of the intestine that includes subtypes of ulcerative colitis (UC) and Crohn's Disease (CD) and currently has no cure. While IBD results from a complex interplay between genetic, environmental, and immunological factors, sequencing advances over the last 10-15 years revealed signature changes in gut microbiota that contribute to the pathogenesis of IBD. These findings highlight IBD as a disease target for microbiome-based therapies, with the potential to treat the underlying microbial pathogenesis and provide adjuvant therapy to the emerging spectrum of advanced therapies for IBD. Building on the success of fecal microbiota transplantation (FMT) for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.